flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 Patients with type 2 #diabetes and chronic disease are at high risk for kidney failure, cardiovascular events, and death. ⁣ ⁣ Whether treatment with would mitigate these risks is unknown. ⁣ ⁣ FLOW clinical Trial (funded by

Genetic Factors That Influence Semaglutide Response Speed Your genetic makeup significantly affects how quickly you'll experience semaglutide's blood sugar benefits

It is important to note that currently only two GLP-1 RA agents have the indication for management of obesity: Wegovy (semaglutide) and Saxenda (liraglutide)

Less attention is paid to whether its safe

Approximately 10-20% of Hashimotos patients have elevated TgAb without elevated TPO antibodies

In addition, cyanocobalamin, a synthetic version of vitamin B12, is often used to treat it

A study by the McLaughlin Group in 2002 delivered numbers that are sobering